Business Context and Reporting Period
This Form 8-K was filed by Savara Inc. (formerly Mast Therapeutics, Inc.) on May 2, 2017. The report details the termination of a material definitive agreement, specifically the "Hercules Loan Agreement" with Hercules Technology III, L.P. and Hercules Capital, Inc.
Key Financial Metrics
- Debt Repayment: The Company repaid all outstanding amounts under the Hercules Loan Agreement totaling approximately $3.67 million.
- Prepayment Premium: The payoff included a 2.0% prepayment premium.
- Liquidity Source: Repayment proceeds were sourced from a new credit facility with Silicon Valley Bank.
- Revenue and Profit: The filing text does not provide a clear value for revenue, profit, cash flow, or margins.
Material Changes
The primary material change is the complete termination of the Hercules Loan Agreement, which had been amended six times since its inception in August 2015. This action eliminated the associated debt obligation and replaced it with financing from Silicon Valley Bank.
Outlook and Management Commentary
The filing does not contain forward-looking guidance, management commentary on future operations, or specific risk factors beyond the context of the debt restructuring. The transaction was executed to refinance existing obligations.
Investor Verification Checklist
- Verify the terms and interest rates of the new credit facility with Silicon Valley Bank.
- Confirm the total cash outflow including the 2.0% prepayment premium on the $3.67 million payoff.
- Review the Company's current liquidity position post-refinancing.
- Check for any covenants in the new Silicon Valley Bank agreement that may impact future operations.